BELLICUM PHARMACEUTICALS, INC: Nasdaq/NYSE listing notice — Bellicum Pharmaceuticals receives delisting notice from Nasdaq; to trade on OTCQX

BELLICUM PHARMACEUTICALS, INC

Nasdaq will suspend trading of BLCM common stock at open on June 2, 2023 due to non-compliance with equity continued listing rule.
Company did not submit a compliance plan to Nasdaq as required by May 19, 2023.
No appeal will be filed; common stock to trade on OTCQX marketplace under symbol BLCM.
Previous disclosure indicated stockholders' equity failed Nasdaq's minimum requirement.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

BELLICUM PHARMACEUTICALS, INC received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

May 24, 2023, the Company received written notification from Nasdaq stating that, subject to the Company’s right to request an appeal, trading of the Company’s common stock will be suspended at the opening of business on June 2, 2023, and a Form 25-NSE will be filed thereafter with the SEC, which will remove the Company’s securities from listing and registration on Nasdaq. The Company does not intend to request an appeal of the delisting determination. The Company anticipates that effective June 2, 2023, the Company’s common stock will commence trading on the OTCQX marketplace under the symbol

View on SEC.gov

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

BELLICUM PHARMACEUTICALS, INC received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

April 6, 2023, the Company received notice from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company’s stockholders’ equity as reported in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 does not satisfy the Nasdaq Capital Market continued listing requirement set forth in Nasdaq Listing Rule 5550(b)(1) (“Rule 5550(b)(1)”). The Company was given until May 19, 2023 to submit to Nasdaq a plan to regain compliance with Rule 5550(b)(1). The Company did not submit such a plan to Nasdaq. As a result, on May 24, 2023, the Company received written notification from Nasd

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001628280-23-020109

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.